# Neuro-Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Rudolph (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML036-SYN
- Date: 2026-07-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Tomasz Brzezinski, MD
- Calendar frame: modern shifted

- Requested by: Gloria Haynes-Whitaker, MD

## Reason for consultation

Three weeks of headaches on waking, with ten days of word-finding pauses and clumsiness of the right hand, in a previously well 54-year-old hospital executive and former Olympic sprinter. Examination today shows mild expressive language difficulty, a slight right pronator drift and right grip weakness. MRI of the brain with and without contrast is booked for tomorrow morning. Please see her within a week, with neurosurgery, to review the MRI with her and plan diagnosis and treatment if it shows a tumor. **S**

## History

Ms. Rudolph, 54, is seen with the neurosurgery team at the request of Dr. Haynes-Whitaker, three days after she reported three weeks of morning headaches and ten days of word-finding pauses and right-hand clumsiness. The MRI the next morning showed a left frontal mass, and dexamethasone 4 mg twice a day was started that afternoon; since then her headache has eased and her speech has improved. CT of the chest, abdomen and pelvis yesterday showed no cancer elsewhere. She has had no seizure. She had polio as a small child, which left her left leg paralyzed for some years; she recovered fully and became an Olympic sprinter. She works as a hospital vice president, is right-handed, and wants the facts given plainly. **S**

## Examination

| System | Finding |
|---|---|
| Mental status and speech | Alert and oriented; fluent with rare word-finding pauses; naming, repetition and comprehension intact |
| Cranial nerves | Mild right nasolabial flattening; no papilledema |
| Motor | Slight right pronator drift; right grip and finger extension 4+/5; legs 5/5 |
| Gait | Steady; tandem gait slightly unsteady |

BP 134/82 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 67.8 kg; BMI 20.9 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Haynes-Whitaker's intake note. MRI of the brain with and without contrast, with diffusion and perfusion: a 3.8 x 3.2 cm ring-enhancing mass in the left posterior frontal lobe involving the posterior inferior frontal gyrus and abutting the precentral gyrus, with central necrosis, raised relative cerebral blood volume in the rim, no restricted diffusion in the necrotic center, surrounding edema and 5 mm midline shift; no other lesion. CT of the chest, abdomen and pelvis: no primary tumor or other lesion. Today: hemoglobin 13.0 g/dL, white cells 11.8 on dexamethasone, platelets 270; sodium 140, potassium 4.0, creatinine 0.84 mg/dL; glucose 138 mg/dL not fasting; INR 1.0, aPTT 29 seconds. Hemoglobin: 13 g/dL; White cell count: 11.8 10*3/uL (high); Platelets: 270 10*3/uL; Sodium: 140 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.84 mg/dL; eGFR (CKD-EPI 2021): 83 mL/min/1.73 m²; Glucose: 138 mg/dL (high); INR: 1; aPTT: 29 s; Karnofsky Performance Status: 80; PHQ-9: 7; GAD-7: 9. All results are synthetic.

## Assessment

1. **Left posterior frontal ring-enhancing mass, presumed high-grade glioma** (D49.6). A single necrotic ring-enhancing mass with raised perfusion in a woman of 54 without cancer elsewhere on CT is most likely a glioblastoma. A solitary metastasis has been made unlikely by the CT; lymphoma would usually enhance solidly and restrict diffusion; an abscess would restrict diffusion in its center. The mass sits just behind the expressive language area and in front of the motor strip, and the edema explains much of her symptoms. Maximal safe resection, rather than biopsy alone, gives the tissue diagnosis, relieves the mass effect and improves survival, and an awake craniotomy with cortical and subcortical language and motor mapping lets the surgeons remove the tumor while protecting speech and hand function. A functional MRI with tractography beforehand will show the language areas and the motor tract. The tissue needs an integrated WHO CNS5 diagnosis: IDH1 R132H immunostaining, with IDH1 and IDH2 sequencing if it is negative because she is 54, ATRX and p53, the TERT promoter, EGFR amplification and chromosome 7 gain with 10 loss, which define glioblastoma when IDH is wild-type, CDKN2A, histone H3 and BRAF, and MGMT promoter methylation, which predicts benefit from temozolomide. If this is a glioblastoma, the standard after surgery is radiotherapy 60 Gy in 30 fractions with daily temozolomide 75 mg/m2, Pneumocystis prophylaxis and weekly blood counts, then six cycles of adjuvant temozolomide, with tumor-treating fields offered for the adjuvant phase, and screening for a clinical trial. Dexamethasone is right for edema causing symptoms and should be tapered as soon as possible after surgery. She has had no seizure, so she should not have a prophylactic antiseizure drug. Brain tumors carry a high risk of venous thromboembolism: she needs mechanical and then heparin prophylaxis in hospital after surgery, but not routinely at home. **S**

## Recommendations

1. Functional MRI with diffusion tensor tractography in four days.
2. Awake left frontal craniotomy with language and motor mapping for maximal safe resection in six days, with an MRI within 48 hours of surgery.
3. Integrated WHO CNS5 diagnosis: IDH1 R132H immunostaining with IDH1 and IDH2 sequencing if negative, ATRX, p53, TERT promoter, EGFR, chromosome 7 and 10, CDKN2A, histone H3, BRAF and MGMT promoter methylation.
4. If glioblastoma: radiotherapy 60 Gy in 30 fractions with temozolomide 75 mg/m2 daily, then six cycles of temozolomide 150 to 200 mg/m2 on days 1 to 5 every 28 days; Pneumocystis prophylaxis during concurrent treatment and while lymphopenia lasts; antiemetic before each dose; tumor-treating fields offered with adjuvant temozolomide; clinical trial screening.
5. Dexamethasone 4 mg twice a day with famotidine until surgery, then a taper to stop within a few weeks; glucose checks while on the steroid.
6. No prophylactic antiseizure drug; levetiracetam if a seizure occurs; seizure first aid for her household.
7. Mechanical and then low-molecular-weight heparin prophylaxis in hospital after surgery; no routine prophylaxis at home; teach the signs of leg clot and pulmonary embolism.
8. For primary care: weekly blood counts during chemoradiation and on day 22 of each adjuvant cycle, liver tests at baseline and before each cycle, MRI four weeks after radiotherapy and then every two to three months read with allowance for pseudoprogression, physical therapy and fall prevention given her new right-sided weakness and old left-leg polio, no driving for now, distress screening, and an early palliative care referral.

## Strengths and supports

- Vice president of a Nashville hospital; former Olympic champion sprinter, teacher and coach; runs a foundation that supports young track and field athletes **S**

## Communication

Discussed with Dr. Haynes-Whitaker, who saw her the same day. The MRI and the plan were explained to Ms. Rudolph with the images, and she agreed to the awake craniotomy; she decides who else receives this note. **S**

## Follow-up

Surgery in six days; review with the integrated diagnosis and the tumor board recommendation before radiotherapy; Dr. Haynes-Whitaker continues primary care and shares the monitoring. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026), National Comprehensive Cancer Network
- Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021), European Association of Neuro-Oncology
- Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251 (PMID 34185076) (2021), Neuro-Oncology (WHO Classification of Tumours)
- Mohile NA, et al. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol 2022;40(4):403-426 (PMID 34898238) (2022), American Society of Clinical Oncology and Society for Neuro-Oncology
- Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005), New England Journal of Medicine
- Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (PMID 15758010) (2005), New England Journal of Medicine
- Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017), JAMA
- Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023), Response Assessment in Neuro-Oncology working group (Journal of Clinical Oncology)
- TEMODAR (temozolomide) capsules, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Merck Sharp & Dohme label)
- Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021), Society for Neuro-Oncology and European Association of Neuro-Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
